Analysis Tools
immune system
| N |
• mice treated with peptidoglycan or muramyl dipeptide (MDP) develop arthritis with the same severity and incidence as in similarly treated wild-type mice
|
|
Allele Symbol Allele Name Allele ID |
Pglyrp4tm1Rdz targeted mutation 1, Roman Dziarski MGI:5297107 |
||||||||||||
| Summary |
2 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• mice treated with peptidoglycan or muramyl dipeptide (MDP) develop arthritis with the same severity and incidence as in similarly treated wild-type mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• severe in DSS-treated mice
|
|
• severe in DSS-treated mice
|
|
• DSS-treated mice exhibit extremely severe intestinal bleeding with mild hyperplasia of the lamina propria, thickened submucosa, loss of morphology and crypt architecture, progressive complete loss of colonic epithelial layer, decrease in goblet cells, and severe ulceration compared with similarly treated wild-type mice
|
|
• DSS-treated mice exhibit thickened submucosa compared with similarly treated wild-type mice
|
|
• decreased in DSS-treated mice compared with similarly treated wild-type mice
|
|
• DSS-treated mice exhibit loss of morphology and crypt architecture compared with similarly treated wild-type mice
|
|
• in DSS-treated mice
|
|
• reduced Lactobacillus/Lactococcus and segmented filamentous bacteria groups
• increased Bacteroides group
|
|
• DDS-treated mice exhibit extremely severe intestinal bleeding with mild hyperplasia of the lamina propria, thickened submucosa, loss of morphology and crypt architecture, progressive complete loss of colonic epithelial layer, decrease in goblet cells, and severe ulceration; accelerated and increased weight loss; and accelerated and higher mortality compared with similarly treated wild-type mice
• mice exhibit increased sensitivity to DSS-induced colitis at 3% or 5% DSS compared with wild-type mice
|
|
• DSS-treated mice exhibit loss of morphology and crypt architecture compared with similarly treated wild-type mice
|
|
• severe in DSS-treated mice
|
|
• in DSS-treated mice
|
|
• DDS-treated mice exhibit extremely severe intestinal bleeding with mild hyperplasia of the lamina propria, thickened submucosa, loss of morphology and crypt architecture, progressive complete loss of colonic epithelial layer, decrease in goblet cells, and severe ulceration; accelerated and increased weight loss; and accelerated and higher mortality compared with similarly treated wild-type mice
• mice exhibit increased sensitivity to DSS-induced colitis at 3% or 5% DSS compared with wild-type mice
|
|
• induced mouse embryonic fibroblasts and peritoneal macrophage exhibit increased CXCL1 production compared with wild-type cells
|
|
• in induced mouse embryonic fibroblasts and peritoneal macrophage
|
|
• in DSS-treated mice
|
|
• decreased in DSS-treated mice compared with similarly treated wild-type mice
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 08/02/2024 MGI 6.24 |
|
|
|
||